Gain of MYCN region in a wilms tumor-derived xenotransplanted cell line

Diagnostic Molecular Pathology

Volumn 19, Issue 1, 2010, Pages 33-39

  Noguera, Rosa ^a   Villamón, Eva ^a   Berbegall, Ana ^a   MacHado, Isidro ^a   Giner, Francisco ^a   Tadeo, Irene ^a   Navarro, Samuel ^a   Llombart Bosch, Antonio ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Genetic alterations; MYCN gain; Nude mice; Wilms tumor

Indexed keywords

DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE REPORT; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; MALE; METASTASIS; MOUSE; NEPHROBLASTOMA; NONHUMAN; NUDE MOUSE; ONCOGENE MYC; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; CHILD, PRESCHOOL; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INDEL MUTATION; MALE; MICE; MICE, NUDE; NUCLEAR PROTEINS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; ONCOGENE PROTEINS; TRANSPLANTATION, HETEROLOGOUS; WILMS TUMOR;

EID: 77749326537     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3181b11a9d     Document Type: Article

References (58)

1. Varan A. Wilms' tumor in children: an overview. Nephron Clin Pract. 2008;108:c83-c90.
2. Ruteshouser EC, Huff V. Familial Wilms tumor. Am J Med Genet C Semin Med Genet. 2004;129C:29-34.
3. Alessandri JL, Cuillier F, Ramful D, et al. Perlman syndrome: report, prenatal findings and review. Am JMed Genet A. 2008;146A: 2532-2537.
4. Auber F, Jeanpierre C, Denamur E, et al. Management of Wilms tumors in Drash and Frasier syndromes. Pediatr Blood Cancer. 2009;52:55-59.
5. Cerrato F, Sparago A, VerDe G, et al. Different mechanisms cause imprinting Defects at the IGF2/H19 locus in Beckwith-WieDemann syndrome and Wilms' tumour. Hum Mol Genet. 2008;17:1427-1435.
6. Terenziani M, SarDella M, Gamba B, et al. A novel WT1 mutation in a 46,XY boy with congenital bilateral cryptorchidism, nystagmus and Wilms tumor. Pediatr Nephrol. 2009;24:1413-1417.
7. Uccini S, Perotti D, Colarossi C, et al. Molecular eviDence of the inDepenDent origin of multiple Wilms tumors in a case of WAGR syndrome. Pediatr Blood Cancer. 2008;51:344-348.
8. Ghanem MA, Van Steenbrugge GJ, Nijman RJ, et al. Prognostic markers in nephroblastoma (Wilms' tumor). Urology. 2005;65: 1047-1054.
9. Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer. 2008;47:461-470.
10. Hing S, Lu YJ, Summersgill B, et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol. 2001;158:393-398.
11. Natrajan R, Little SE, Sodha N, et al. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J Pathol. 2007;211:52-59.
12. Routh JC, Ashley RA, Sebo TJ, et al. B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J Urol. 2008;179:1954-1959; discussion 1959-1960.
13. Wittmann S, Zirn B, Alkassar M, et al. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis. Genes Chromosomes Cancer. 2007;46:163-170.
14. Schaub R, Burger A, Bausch D, et al. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors. Cancer Genet Cytogenet. 2007;172:61-65.
15. Faussillon M, Murakami I, Bichat M, et al. Molecular cytogenetic anomalies and phenotype alterations in a newly established cell line from Wilms tumor with diffuse anaplasia. Cancer Genet Cytogenet. 2008;184:22-30.
16. Rassekh SR, Chan S, Harvard C, et al. Screening for submicroscopic chromosomal rearrangements in Wilms tumor using wholegenome microarrays. Cancer Genet Cytogenet. 2008;182:84-94.
17. Zhou D, Ren Z. Multiplex ligation-DepenDent probe amplification and its application. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2009; 26:45-49.
18. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-DepenDent probe amplification. Nucleic Acids Res. 2002;30:e57.
19. Alibakhshi R, Kianishirazi R, Cassiman JJ, et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: iDentification of eight novel mutations. J Cyst Fibros. 2008;7:102-109.
20. Erlandson A, Samuelsson L, Hagberg B, et al. Multiplex ligationDepenDent probe amplification (MLPA) Detects large Deletions in the MECP2 gene of Swedish Rett syndrome patients. Genet Test. 2003; 7:329-332.
21. Hogervorst FB, NeDerlof PM, Gille JJ, et al. Large genomic Deletions and duplications in the BRCA1 gene iDentified by a novel quantitative method. Cancer Res. 2003;63:1449-1453.
22. Jeuken J, Cornelissen S, Boots-Sprenger S, et al. Multiplex ligationDepenDent probe amplification: a diagnostic tool for simultaneous iDentification of different genetic markers in glial tumors. J Mol Diagn. 2006;8:433-443.
23. Nakagawa H, Hampel H, De la Chapelle A. IDentification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques. Hum Mutat. 2003;22:258.
24. Villamon E, Piqueras M, Mackintosh C, et al. Comparison of different techniques for the Detection of genetic risk-iDentifying chromosomal gains and losses in neuroblastoma. Virchows Arch. 2008;453:47-55.
25. Jalali GR, Vorstman JA, Errami A, et al. Detailed analysis of 22q11.2 with a high Density MLPA probe set. Hum Mutat. 2008; 29:433-440.
26. Priolo M, Sparago A, Mammi C, et al. MS-MLPA is a specific and sensitive technique for Detecting all chromosome 11p15.5 imprinting Defects of BWS and SRS in a single-tube experiment. Eur J Hum Genet. 2008;16:565-571.
27. ReDeker EJ, De Visser AS, Bergen AA, et al. Multiplex ligationDepenDent probe amplification (MLPA) enhances the molecular diagnosis of aniridia and related disorDers. Mol Vis. 2008;14: 836-840.
28. Scott RH, Douglas J, Baskcomb L, et al. Methylation-specific multiplex ligation-DepenDent probe amplification (MS-MLPA) robustly Detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation. J Med Genet. 2008;45: 106-113.
29. Stachon AC, Baskin B, Smith AC, et al. Molecular diagnosis of 22q11.2 Deletion and duplication by multiplex ligation DepenDent probe amplification. Am J Med Genet A. 2007;143A: 2924-2930.
30. Zeschnigk M, Albrecht B, Buiting K, et al. IGF2/H19 hypomethylation in Silver-Russell syndrome and isolated hemihypoplasia. Eur J Hum Genet. 2008;16:328-334.
31. Wittmann S, WunDer C, Zirn B, et al. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer. 2008;47:386-395.
32. Rivera MN, Kim WJ, Wells J, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 2007;315: 642-645.
33. Celiker MY, Wang M, Atsidaftos E, et al. Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA. Oncogene. 2001;20: 4337-4343.
34. Garvin AJ, Congleton L, Inabnett T, et al. Growth characteristics of human Wilms' tumor in nuDe mice. Pediatr Pathol. 1988;8: 599-615.
35. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunoDeficient mice. Nat Protoc. 2007;2:247-250.
36. Burgues O, Navarro S, Noguera R, et al. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Virchows Arch. 2006;449:410-420.
37. Ambros PF, Ambros IM, BroDeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009;100:1471-1482.
38. Piqueras M, Navarro S, Castel V, et al. Analysis of biological prognostic factors using tissue microarrays in neuroblastic tumors. Pediatr Blood Cancer. 2009;52:209-214.
39. Hoglund M, Gisselsson D, Hansen GB, et al. Wilms tumors Develop through two distinct karyotypic pathways. Cancer Genet Cytogenet. 2004;150:9-15.
40. Mertens F, Johansson B, Hoglund M, et al. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res. 1997;57:2765-2780.
41. Bown N, Cotterill SJ, Roberts P, et al. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the UK cancer cytogenetics group and the UK Children's Cancer Study Group. Med Pediatr Oncol. 2002;38:11-21.
42. Slater RM, Mannens MM. Cytogenetics and molecular genetics of Wilms' tumor of childhood. Cancer Genet Cytogenet. 1992;61: 111-121.
43. Klamt B, Schulze M, Thate C, et al. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters. Genes Chromosomes Cancer. 1998;22:287-294.
44. Law MH, Algar E, Little M. Allelic imbalance at chromosome 1q21 in Wilms tumor. Cancer Genet Cytogenet. 1997;97:54-59.
45. Maiti S, Alam R, Amos CI, et al. Frequent association of betacatenin and WT1 mutations in Wilms tumors. Cancer Res. 2000; 60:6288-6292.
46. Powlesland RM, Charles AK, Malik KT, et al. Loss of heterozygosity at 7p in Wilms' tumour Development. Br J Cancer. 2000; 82:323-329.
47. AnDerson CE, Punnett HH, Huff V, et al. Characterization of a Wilms tumor in a 9-year-old girl with trisomy 18. Am J Med Genet A. 2003;121A:52-55.
48. Peier AM, Meloni AM, Erling MA, et al. Involvement of chromosome 7 in Wilms tumor. Cancer Genet Cytogenet. 1995;79: 92-94.
49. Defferrari R, Tonini GP, Conte M, et al. Concomitant DDX1 and MYCN gain in neuroblastoma. Cancer Lett. 2007;256:56-63.
50. Getman ME, Houseal TW, Miller GA, et al. Comparative genomic hybridization and its application toWilms' tumorigenesis. Cytogenet Cell Genet. 1998;82:284-290.
51. Steenman M, ReDeker B, De Meulemeester M, et al. Comparative genomic hybridization analysis of Wilms tumors. Cytogenet Cell Genet. 1997;77:296-303.
52. Schlomm T, Gunawan B, Schulten HJ, et al. Effects of chemotherapy on the cytogenetic constitution of Wilms' tumor. Clin Cancer Res. 2005;11:4382-4387.
53. Corvi R, Savelyeva L, Schwab M. Duplication of N-MYC at its resiDent site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells. Cancer Res. 1995; 55:3471-3474.
54. Ambros IM, Benard J, Boavida M, et al. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol. 2003; 21:2077-2084.
55. Cohn SL, Tweddle DA. MYCN amplification remains prognostically strong 20 years after its "clinical Debut". Eur J Cancer. 2004;40:2639-2642.
56. Gupta A, Kessler P, Rawwas J, et al. Regulation of CRABP-II expression by MycN in Wilms tumor. Exp Cell Res. 2008;314: 3663-3668.
57. Ambros IM, Hata J, Joshi VV, et al. Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups. Cancer. 2002;94:1574-1583.
58. Tang XX, Zhao H, Kung B, et al. The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res. 2006;66: 2826-2833.